Vincerx Pharma, Inc. (VINC)

US — Healthcare Sector
Peers: SPRO  BOLT  CHRS  GRCL  NLTX  APLT  LYRA  STTK  BCAB  MNPR  SNTI  PCSA  FRTX  LVTX  TCON  RZLT  XOMA  SIOX  TARA  VCNX  MIRO  SRZN 

Automate Your Wheel Strategy on VINC

With Tiblio's Option Bot, you can configure your own wheel strategy including VINC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol VINC
  • Rev/Share 0.0
  • Book/Share 0.5771
  • PB 0.084
  • Debt/Equity 0.0
  • CurrentRatio 1.7885
  • ROIC -13.0942

 

  • MktCap 253863.0
  • FreeCF/Share -6.3804
  • PFCF -0.0111
  • PE -0.0077
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -3.0866

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Vincerx Pharma, Inc. (VINC)

  • IPO Date 2020-05-27
  • Website https://vincerx.com
  • Industry Biotechnology
  • CEO Dr. Raquel E. Izumi Ph.D.
  • Employees 12

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.